



B1 804
1647

Dkt. 41426-D/JPW/BJA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ron S. Israeli et al.

Serial No.: 08/470,735 Group Art Unit: 1647

Filed: June 6, 1995 Examiner: S. Gucker

For: PROSTATE-SPECIFIC MEMBRANE ANTIGEN

Date of Notice

Of Allowance: April 20, 2004

Confirmation No.: 7764

1185 Avenue of the Americas
New York, New York 10036
May 31, 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following disclosure which is listed on the attached Form PTO-1449 (**EXHIBIT A**). A copy of the disclosures listed below as items 1-2 are attached hereto as **EXHIBITS 1-4**:

1. Holmes, Eric H., "PSMA Specific Antibodies And Their Diagnostic And Therapeutic Use," *Exp. Opin. On Invest. Drugs*, 10(3):511-519 (2001); (**Exhibit 1**)
2. Communication Pursuant To Article 115(2) EPC issued August 30, 2004 in connection with related European Patent Application No. 94 90 0538.3; (**Exhibit 2**)
3. Communication Pursuant To Article 96(2) EPC issued February 8, 2005 in connection with related European Patent Application No. 94 90 0538.3 (**EXHIBIT 3**); and


Applicants: Ron S. Israeli et al.
U.S. Serial No.: 08/403,803
Filed: March 17, 1995
Page 2 of 2


4. Communication Pursuant To Article 115(2) EPC issued March 17, 2005 in connection with related European Patent Application No. 94 90 0538.3 (EXHIBIT 4).


If a telephone conference would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Third Supplemental Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:	
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	
	5/31/05
John P. White Reg. No. 28,678	Date


John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	08/470,735
		Filing Date	June 6, 1995
		First Named Inventor	Ron S. Israeli
		Art Unit	1647
Examiner Name	S. Gucker		
Sheet 1	of 1	Attorney Docket Number	1769/41426-D/JPW/BJA

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	HOLMES, ERIC H., "PSMA Specific Antibodies And Their Diagnostic And Therapeutic Use," Exp. Opin. On Invest. Drugs, 10(3):511-519 (2001);	
	2	Communication Pursuant To Article 115(2) EPC issued August 30, 2004 in connection with related European Patent Application No. 94 90 0538.3;	
	3	Communication Pursuant To Article 96(2) EPC issued February 8, 2005 in connection with related European Patent Application No. 94 90 0538.3;	
	4	Communication Pursuant To Article 115(2) EPC issued March 17, 2005 in connection with related European Patent Application No. 94 90 0538.3.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicants: Ron S. Israeli et al.
Serial No.: 08/470,735
Filed: June 6, 1995
Exhibit A